Voxsanity

Who may be able to join

Who might be able to join this trial:

You have already fully completed the treatment period in a previous related study called PTC518-CNS-002-HD.

Who may not be able to join:

You have not completed the full treatment period in the previous related study called PTC518-CNS-002-HD.

Important: Always verify eligibility with the trial site directly before applying.

Note: The official criteria state that other inclusion and exclusion requirements may also apply that are not listed here — please confirm all details directly with the trial site.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status

Active, Not Recruiting

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Registry

clinicaltrials_gov

Start date

25 August 2023

Est. completion

16 July 2029

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇨🇦 Canada 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇳🇱 Netherlands 🇳🇿 New Zealand 🇪🇸 Spain 🇬🇧 United Kingdom

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants With Treatment-emergent Adverse Events (TEAEs); Blood Total Huntingtin Protein (tHTT) Levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov